[Sarcoid uveitis: Ophthalmologist's and internist's viewpoints]. / Uvéites sarcoïdosiques : regards croisés de l'ophtalmologiste et de l'interniste.
Rev Med Interne
; 44(3): 112-122, 2023 Mar.
Article
en Fr
| MEDLINE
| ID: mdl-36642624
ABSTRACT
Sarcoidosis is one of the leading causes of inflammatory eye disease. All ocular structures can be affected, but uveitis is the main manifestation responsible for vision loss in ocular sarcoidosis. Typical sarcoid anterior uveitis presents with mutton-fat keratic precipitates, iris nodules, and posterior synechiae. Posterior involvement includes vitritis, vasculitis, and choroidal lesions. Cystoid macular edema is the most important and sight-threatening consequence of sarcoid uveitis. Patients with clinically isolated uveitis at diagnosis rarely develop other organ involvement. Even though, ocular sarcoidosis can have a severe impact on visual prognosis, early diagnosis and a wider range of available therapies (including intravitreal implants) have lessened the functional impact of the disease, particularly in the last decade. Corticosteroids are the cornerstone of treatment for sarcoidosis, but up to 30% of patients achieve remission with requiring high-dose systemic steroids. In these cases, the use of steroid-sparing immunosuppressive therapy (such as methotrexate) is unavoidable. Among these immunosuppressive treatments, anti TNF-α drugs have been a revolution in the management of non-infectious uveitis.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Sarcoidosis
/
Uveítis
/
Oftalmólogos
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
/
Prognostic_studies
/
Screening_studies
Límite:
Humans
Idioma:
Fr
Revista:
Rev Med Interne
Año:
2023
Tipo del documento:
Article